Rabat, Morocco, June 03, 2026 (GLOBE NEWSWIRE) -- Tax leaders from across the continent are meeting in Morocco's capital city to discuss the impact of international tax issues on Africa, in the 11th edition of the Africa Tax Symposium (ATS). Held in a North African country for the first time, the topical ATS programme will run from 3 to 5 June 2026.
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
BEIJING, China, June 03, 2026 (GLOBE NEWSWIRE) -- Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended March 31, 2026.
TORONTO, June 03, 2026 (GLOBE NEWSWIRE) -- The Greater Toronto Area (GTA) resale housing market tightened in May 2026 compared to last year. Sales increased year-over-year, whereas new listings declined over the same period. As standing inventory has been absorbed, competition between buyers has likely increased in some neighbourhoods. This should see the price trend flatten and ultimately trend upwards in the months ahead.
VÅRGÅRDA, Sweden, June 3, 2026 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, is taking a significant step...
GENEVA, June 3, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics,...
HONG KONG, June 3, 2026 /PRNewswire/ -- At Tencent Cloud Day Hong Kong, Tencent Cloud, the cloud business of Tencent, announced its partnership with UXSoft...
Appointment marks the next phase of growth across Digital Public Infrastructure, AI-enabled enterprise solutions and international marketsMUMBAI, India, June 3, 2026 /PRNewswire/ -- Protean...
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
GRENOBLE, France, June 3, 2026 /PRNewswire/ -- Quobly, a French quantum computing company, today announced the closing of a €115 million Series A financing...
The Claims Conference Releases A Cutting-Edge Mixed-Reality Experience Detailing The Heartbreaking And Inspiring Story Of Benno Kern, From Anschluss To Auschwitz To Liberation In Buchenwald.NEW...